Biotech industry seeks control of its destiny
Human Genome Sciences and a small but determined group of its peers are charting unconventional territory. Their efforts to take over the production, sales and marketing of selected portions of their portfolios signals a potential turning point in the industry. The companies contend that they can and should own more of the process that delivers biotechnology’s molecules to market – a process now firmly in the control of the pharmaceutical industry.
Singapore’s biotech bid
Singapore is rolling out the red carpet to foreign scientists and entrepreneurs in an ambitious bid to build up its biotech sector. The government has set aside $2 billion for research in biotech, health care and medical technology until 2005, and pledged $285 million for science scholarships.
Big Pharma: Getting Too Big for Its Own Good?
A study by McKinsey & Co. earlier this year looked at the net present value of products out of research vs. the spending on R&D for the top pharma players over the last decade. It found no correlation between the return on investment and a company’s size
European Patent Office bars human cloning in patent
The European Patent Office added restrictions on Wednesday to a controversial patent granted in 1999 to prevent it being used to clone humans, a ruling limiting biotech research in Europe.
Woman carries human clone, group says
fringe religious movement’s South Korea-based scientific team yesterday said they had implanted a cloned human embryo in a woman, the latest of a string of similar uncomfirmed experiments to emerge from the underground field of human cloning.
Monoclonal Antibodies Look to a Bright Future
Using mAbs as therapeutics could cut preclinical development time by as much as two-thirds and cost by even greater levels.
Genomics Sector Has Fired More Than 1,500 Staff Since January 2001
The following is a general compilation of the number of employees at genomic tool and tech firms who have lost their jobs as the industry, bookended by slowdowns at biotech and pharma customers, struggles to stay afloat.
Biotech Not Cratering, Just Deflating
To see where the biotech sector is headed tomorrow, it might be helpful for investors to look back, and more importantly, forget about, the recent past.
Cuba seeks new drug markets
Inside modern towers that are a pride of Fidel Castro, scientists peer through huge microscopes at tiny proteins they hope to tailor to treat such major killers as AIDS, heart disease and cancer.
Time to Let the Air Out
If you think biotech stocks are headed for a breakout anytime soon, allow us to burst your bubble